EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today reported financial and operating results for the second quarter ended June 30, 2011.
Quarter and Recent Highlights
- Increased both product revenue and total revenue quarter over quarter and year over year.
- Announced positive results from a VIBEX™ MTX clinical pharmacokinetic trial in patients with rheumatoid arthritis (RA) and remain on track for a New Drug Application (NDA) filing in 2012. An additional patent application has been filed based on the data obtained from the study results.
